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IRTA1 and IRTA2, Novel Immunoglobulin Superfamily
Receptors Expressed in B Cells and Involved in
Chromosome 1q21 Abnormalities in B Cell Malignancy
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Their pathogenesis has been elucidated by the charac-
terization of recurrent clonal chromosomal transloca-
tions, whose consequence is the transcriptional deregu-
lation of protooncogenes juxtaposed to heterologous
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The high frequency of involvement of 1q21 structuralSummary
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locus may harbor genes critical to their pathogenesis.Abnormalities of chromosome 1q21 are common in B
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cases (Willis et al., 1998). Characterization of thecell line, we have identified two novel genes, IRTA1 and
t(1;22)(q22;q11) in an FL cell line identified FCGR2B asIRTA2, encoding cell surface receptors homologous to
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Results of this protein include a signal peptide, in accordance
with the [-3, -1] rule (von Heijne, 1986), four extracellular
Ig-type domains carrying three potential asparagine (N)-Molecular Cloning of the t(1;14)(q21;q32)
To clone the 1q21 breakpoint region in FR4, an MM cell linked glycosylation sites (Figure 2A), a 16 amino acid
transmembrane, and a 106 amino acid cytoplasmic do-line with a t(1;14)(q21;q32) (Tagawa et al., 1990), we
performed Southern blot hybridization assays aimed at main with three putative consensus Src-homology 2
(SH2) binding domains (Unkeless and Jin, 1997) (Figureidentifying illegitimately rearranged IGH constant region
(CH) alleles that lost their syntenic association with IGH 2C). These domains exhibit features of both ITAM (im-
mune-receptor tyrosine-based activation motif) (Reth,joining (JH) and 59 switch region (S) sequences (Neri et
al., 1991; Bergsagel et al., 1996). Two “illegitimately” 1992) and ITIM (immune-receptor tyrosine-based inhibi-
tion motif) (Unkeless and Jin, 1997). As shown in Figurerearranged fragments were identified within the Ca
heavy chain locus in FR4 (data not shown) and were 2C, the first two SH2 binding domains are spaced eight
amino acids apart, consistent with the consensus ITAM.cloned from phage libraries constructed from FR4 geno-
mic DNA. Restriction mapping, Southern blot hybridiza- Diverging from the consensus, the glutamate residue
(E) is positioned four rather than two amino acids beforetion, and partial nucleotide (nt) sequencing of two geno-
mic phages demonstrated that they contained the the first tyrosine (Y) (Figure 2C), and valine (V) rather
than leucine (L) or isoleucine (I) occupies the 13 positionchromosomal breakpoints of a reciprocal balanced
translocation between the Ca1 locus on 14q32 and non- relative to tyrosine (Y) (Reth, 1992). All three domains
conform to the ITIM consensus and each is encoded byIGH sequences (Figure 1A). Fluorescence in situ hybrid-
ization (FISH) analysis of normal human metaphase a separate exon, like ITIM. Thus, their arrangement may
give rise either to three ITIM or to one ITAM and onespreads using a 100 kb nonchimeric PAC clone (isolated
with a probe [1.0 EH] representing non-IGH sequences) ITIM. The overall structure of this protein suggests that
it represents a novel transmembrane receptor of the Igidentified the partner chromosomal locus as band 1q21
(Figures 1C and 5). superfamily, and it was therefore named IRTA1 (immune
receptor translocation associated protein 1).Sequence analysis and alignment of the breakpoint
regions with the germline 14q32 and 1q21 loci revealed The second cDNA shares homology to IRTA1 (68%
nt identity for the length of the IRTA1 message encodingthat the translocation had occurred in the intron between
the CH3 and the transmembrane exon of Ca1 on chromo- its extracellular domain) and was named IRTA2. The
IRTA2 locus is more complex than IRTA1 and is tran-some 14. Although the breakpoint was devoid of recom-
bination signal sequences (RSS) or switch signal se- scribed into three major mRNA isoforms (IRTA2a, IR-
TA2b, and IRTA2c), each of which has its own uniquequences (Kuppers et al., 1999), the sequence CTTAAC
(underlined on Figure 1B) was present in both germline 39 UTR (Figure 2A). A minor 0.6 kb isoform (Figure 4A)
arises through the usage of an early polyadenylationchromosomes 14 and 1 at the breakpoint junction (with
a slight modification in the der(1) copy: C to G mutation signal. The three predicted IRTA2 protein isoforms en-
coded by these transcripts share a common amino acidin the last nucleotide). The nucleotides AT preceding
CTTAAC on chromosome 1 were also present in both sequence until residue 560, featuring a common signal
peptide and six extracellular Ig-type domains (Figurederivative chromosomes (Figure 1B). Overall, the fea-
tures of the t(1;14)(q21;q32) breakpoints in FR4 cells 2A). IRTA2a represents a 759 aa secreted glycoprotein
with eight Ig-type domains followed by 13 unique, pre-were consistent with a balanced reciprocal translocation
possibly facilitated by the presence of homologous se- dominantly polar amino acids at its C terminus. IRTA2b
diverges from IRTA2a at amino acid residue 560 andquences (CTTAAC) on both chromosomes (Roth and
Wilson, 1986). extends for a short stretch of 32 additional residues,
whose hydrophobicity is compatible with its docking to
the plasma membrane via a GPI anchor (Ferguson andThe 1q21 Breakpoint Region Contains Genes Coding
Williams, 1988). IRTA2c is the longest isoform whosefor Novel Members of the Immunoglobulin
sequence deviates from IRTA2a at amino acid 746. ItReceptor Superfamily
encodes a 977 aa type I transmembrane glycoproteinCandidate genes located at the breakpoint region were
with nine extracellular Ig-type domains, harboring eightsought by exon trapping (Drakopoli et al., 1997) and by
potential N-linked glycosylation sites, a 23 amino acidsample sequencing of PAC clones 49A16 and 210K22
transmembrane, and a 104 amino acid cytoplasmic do-(see below, Figure 5). This approach led to the identifica-
main with three consensus SH2 binding motifs (Figuretion of two trapped exons belonging to the same tran-
2C). Each of the SH2 binding sites in IRTA2c agreesscript and spanning the FR4 breakpoint (Figure 5). The
with the ITIM consensus (Figure 2C) and is encoded byscreening of a spleen cDNA library with an RT-PCR
a separate exon. These features suggest that IRTA2c isprobe containing both exons yielded two sets of cDNA
a novel transmembrane receptor of the Ig superfamilyclones belonging to two distinct transcripts and sharing
with secreted and GPI-linked isoforms.a 76% mRNA sequence identity within the 443 bp probe
region.
The schematic structure of the cDNA representing the Homology between the IRTA Proteins and
Immunoglobulin Superfamily Receptorsfirst transcript is depicted in Figure 2A. Alternate usage
of three potential polyadenylation sites in its 39 untrans- Amino acid alignment of the entire extracellular domains
of the IRTA1 and IRTA2 proteins to other Ig superfamilylated region (UTR) gives rise to three mRNA species of
2.5, 2.7, and 3.5 kb, encoding the same putative 515 members revealed a remarkable homology between
them (47% identity and 51% similarity) and a lower, butamino acid protein (Figure 2A). The predicted features
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Figure 1. Molecular Cloning of the t(1;14)(q21;q32) in the FR4 MM Cell Line
(A) Schematic representation of the phage clones representing der(14) and der(1) and of the germline IGH and 1q21 loci. Solid black line,
chromosome 14; black boxes, Ca1 exons; and gray line, chromosome 1. Probes used for mapping are indicated. For enzymes marked by an
asterisk, only sites delineating the probes are shown. B, BamHI; H, HindIII; X, XhoI; S, SacI; E, EcoRI; Sa, IgA switch region; and LCR, 39IGH
locus control region.
(B) Nucleotide (nt) sequences of the breakpoint junctions and their alignment to the germline regions of chromosomes 14 and 1. A 16 nt
deletion (GGCACCTCCCCTTAAC) is found in the chromosome 14 portion of der(1) and a 4 nt deletion (TGCA) 6 nt upstream.
(C) Left, FISH analysis on human normal metaphase spreads with PAC 49A16 (Figure 5). Right, DAPI stained image from the same metaphase
spread.
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Figure 2. Structure of IRTA1 and IRTA2 cDNAs and Comparison of Their Predicted Amino Acid Sequences with Members of the Fc Receptor
Family
(A) Schematic representation of the IRTA1 (left) and IRTA2 (right) cDNAs. Pattern-filled wide boxes, coding domains; narrow boxes, untranslated
regions (UTR); arrowhead, signal peptidase cleavage site (SignalIP World Wide Web server at http://www.cbs.dtu.dk/services/SignalIP); TM
domain prediction algorithm, Tusnady and Simon (1998). Arrows in the IRTA1 39 UTR indicate distinct polyadenylation addition sites. Alternative
39UTR regions in IRTA2 isoforms are differentially shaded. Bars underneath the UTR regions identify probes for Northern blot analysis in
Figures 3, 4, and 7.
(B) Multiple sequence alignment of the first two (top) and the third (bottom) extracellular Ig domains of IRTA1 and IRTA2 to Fc receptor family
members, using the ClustalW program (Thompson et al., 1994). Black-shaded boxes, conserved amino acids among all sequences; dark-gray
shaded boxes, conserved amino acids among .50% of the sequences; and light-shaded boxes, conservative substitutions.
(C) Alignment of the SH2 binding domains of IRTA1 and IRTA2 with the ITAM and ITIM consensus. Conserved amino acid positions are in
bold. X, any amino acid; SP, signal peptide; EC, extracellular domain; Ig, immunoglobulin-type; TM, transmembrane domain; CYT, cytoplasmic
domain; A(n), polyA tail; and GPI, glycophosphatidyl inositol.
striking, homology to the Fc receptor family of proteins. BGP1 (30% identity, 35% homology), and IRTA2c and
PECAM1 (28% identity, 50% homology) (Figure 2C).Among Fc receptors, the high-affinity IgG receptor
FCGRI (CD64) shared the highest levels of homology These homologies suggest employment of similar
downstream signaling pathways by these different pro-with the first three Ig domains of IRTA1 and IRTA2 (37%
identity and 50% similarity) throughout its entire extra- teins.
cellular portion (Figure 2B). Lower levels of homology
were observed with the extracellular domains of other IRTA1 and IRTA2 Are Normally Expressed
in Specific Subpopulations of B Cellscell surface molecules, including human platelet endo-
thelial cell adhesion molecule (PECAM1), B lymphocyte Northern blot analysis detected very low levels of IRTA1
expression in human spleen and lymph node RNA (Fig-cell adhesion molecule (CD22), and Biliary Glycoprotein
1 (BGP1) (22%–25% identity, 38%–41% homology). ure 3A, left panel) and no expression in any other human
tissues analyzed (fetal liver, bone marrow, lung, pla-No homology is apparent between the IRTAs and
members of the Fc receptor family in their transmem- centa, small intestine, kidney, liver, colon, skeletal mus-
cle, heart, and brain; data not shown). Among B cellbrane and cytoplasmic domains. In contrast, signifi-
cant amino acid homology exists between IRTA1 and lines, IRTA1 expression was absent from those repre-
senting pre-B, GC, and plasma B cells and cells of ery-PECAM1 (31% identity and 45% homology), IRTA2c and
IRTAs, Immune Receptors Expressed in B Cells
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Figure 3. IRTA1 Expression Pattern
(A) (Left panel) Northern blot analysis of IRTA1 expression in tissues of the human immune system (2 mg mRNA per lane). Bars, RNA molecular
weight markers; arrows, IRTA1 and GAPDH transcripts (a GAPDH probe was included in the hybridization as an internal control: 0.15 ng
labeled 1 50 ng unlabeled probe).
(Right panel) Northern blot analysis of IRTA1 expression in total RNA from the ER/EB cell line (10 mg per lane). Cells were grown in the
presence of estrogen (1 mg/ml), followed by estrogen withdrawal for the indicated times. Arrows, positions of corresponding mRNAs (a, b,
and c: differentially polyadenylated IRTA1 species). The same blot was stripped and reprobed with a MYC cDNA probe (exon 2) to verify G0/
G1 arrest. Densitometric analysis of IRTA1 mRNA levels is plotted in the adjacent column graph.
(B) In situ hybridization analysis of IRTA1 expression in serial sections of human tonsil. 1. Sense IRTA1 probe 2. Antisense IRTA1 probe 3.
H&E staining 4. Antisense IRTA1 signal superimposed over an H&E stained section. GC, germinal center, and MargZ, marginal zone.
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throid, T cell, and myeloid origin (data not shown) and first determined the organization of their genomic loci.
was detectable at very low levels only in EBV-immortal- The IRTA1 and IRTA2 genes are located within a 21 kb
ized lymphoblastoid cell lines. However, IRTA1 expres- distance from each other and share the same transcrip-
sion was induced (by 10-fold) in estrogen-deprived ER/ tional orientation (telomere -59-39- centromere) (Figure
EB cells, which, being immortalized by a recombinant 5). At the 1q21 locus, they form a contig with three
EBV genome in which the EBNA2 gene is fused to the additional IRTA related genes (IRTA3, 4, and 5; I. M,
estrogen receptor, proliferate in the presence of estro- unpublished data), covering an z300 kb region at the
gen but arrest in the G0/G1 phase upon estrogen with- interval between previously reported 1q21 breakpoints.
drawal (Kempkes et al., 1995) (Figure 3A, right panel). Based on the genomic distance between clones harbor-
Taken together, these results suggest that IRTA1 is ex- ing the respective genes on the Whitehead Institute Ra-
pressed in a lymphoid subpopulation present in spleen diation Hybrid map, the IRTA1-2 locus is placed at a
and lymph nodes and presumably represented by rest- telomeric distance of z0.8 Mb relative to the MUC1
ing B cells. locus (N. P, unpublished data) and at a centromeric
To further investigate the phenotype and tissue distri- distance less than or equal to 7 Mb to the FCGRIIB locus
bution of the cells expressing IRTA1, we performed in (N. P, unpublished data).
situ hybridization on human tonsillar tissue using an
IRTA1 antisense cDNA probe (Figure 3B). The IRTA1 The t(1;14)(q21;q32) Generates an IRTA1/Ca1 Fusion
hybridization signal was excluded from the GC and the Protein in the FR4 Myeloma Cell Line
mantle zone of the follicles and was characteristically Since the t(1;14)(q21;q32) in FR4 had fused sequences
concentrated in the perifollicular zone with infiltrations within intron 2 of the IRTA1 gene to the intronic se-
in the intraepithelial region (Figures 3B-2 and 3B-4). In quences preceding the transmembrane exon of Ca1 in
this region, only B cells were positive as documented the same transcriptional orientation (Figure 6A), we as-
by staining with B cell–specific markers (IgD, data not sayed for the presence of a fusion IRTA1/Ca1 mRNA,
shown) and by immunohistochemical analysis with anti- and possibly a IRTA1/Ca1 fusion protein, in FR4 by
IRTA1 and anti-B (CD20, PAX5), anti-T (CD3), and anti- Northern blot analysis. Using an IRTA1 cDNA probe de-
monocyte (CD68) antibodies (data not shown; G. C. et rived from exon 1 (Figure 6A), we detected a 0.8 kb
al., unpublished data). This perifollicular area is the message in FR4 that was absent from other B cell lines
“marginal zone” equivalent of the tonsil, representing a and was shorter than the normal 2.5 kb message detect-
functionally distinct B cell compartment that contains able in ER/EB cells (Figure 6B). We cloned this transcript
mostly memory B cells and monocytoid B cells (de Wolf- by RT-PCR of FR4 mRNA using primers derived from
Peeters et al., 1997). Together with the Northern blot sequences at the 59 border of IRTA1 exon 1 and the 39
analysis of normal tissues and cell lines, these results border of the Ca cytoplasmic exon (Figure 6A). An RT-
indicate that IRTA1 is expressed in a subpopulation of PCR product was obtained from FR4 but not from the
resting mature B cells topographically located in the DAKIKI cell line expressing wild-type surface IgA or
perifollicular and intraepithelial region, sites rich in mem- other cell lines lacking a t(1;14) translocation (data not
ory B cells.
shown). Direct sequencing analysis of the PCR product
In the case of IRTA2, Northern blot analysis detected
indicated that splicing had precisely linked IRTA1 and
all alternatively spliced species in human lymph node,
Ca1 at canonical splicing sites and determined that thespleen, bone marrow, and small intestine mRNA, with
fusion transcript was 820 bp long.relative preponderance of the IRTA2a isoform (Figure
Analysis of the predicted protein product indicated4A, left panel). Among the hematopoietic cell lines of
that the IRTA1/Ca1 splicing had resulted in a fusion be-lymphoid and nonlymphoid origin tested, IRTA2 expres-
tween the IRTA1 signal peptide and first two extracellu-sion was restricted to B cell lines with an immunoblastic,
lar amino acids, with the 32 amino acid long extracellularpost-GC phenotype (Figure 4A, right panel).
spacer, transmembrane domain, and cytoplasmic tail ofIn situ hybridization analysis of human tonsillar tissue,
the membrane IgA1 (mIgA1) receptor (Figure 6C). Weusing the IRTA2c cDNA as a probe, was consistent with
assayed for the expression of this fusion protein in FR4the results of the Northern blot analysis. The IRTA2
protein extracts, with an antibody directed against ex-mRNA was largely excluded from the mantle zone of
tracellular amino acid residues specific for the trans-the GC, with the exception of a few positive cells (Figures
membrane isoform of Ca1 (Yu et al., 1990) by immuno-4B-2 and 4B-4). Within the GC, the dark zone, repre-
precipitation, followed by Western blotting. Our resultssented by centroblasts, appeared negative, while the
demonstrated that FR4 cells, but not a control cell linelight zone, rich in centrocytes, was strongly positive
(DAKIKI) expressing wild-type surface IgA, express a(Figures 4B-2 and 4B-4). Finally, IRTA2 mRNA was de-
9.8 kDa protein consistent with the predicted size oftected in the “marginal zone” equivalent region outside
IRTA1/Ca1 fusion protein (Figure 6D). These results showGC follicles and in the intraepithelial and interfollicular
that the translocated allele encodes a fusion protein,regions of the tonsil. This pattern is consistent with spec-
composed of the signal peptide and first two extracellu-ificity of IRTA2 for centrocytes and post-GC B cells. We
lar residues of IRTA1 (17 amino acids) fused to the Ca1conclude that both IRTA1 and IRTA2 are specific for
encoded transmembrane and cytoplasmic domains (71mature B cells but IRTA2 has a broader pattern of ex-
amino acids). In contrast to IRTA1/Ca1 overexpressionpression that includes centrocytes and interfollicular B
on der(14), no expression was detected in FR4 for thecells, while IRTA1 is restricted to marginal zone B cells.
reciprocal Ca1/IRTA1 transcript or for the intact IRTA2
gene on der(1).Genomic Organization of the IRTA1 and IRTA2 Genes
With the exception of FR4, IRTA1 mRNA expressionTo understand the consequences of 1q21 abnormalities
on IRTA1 and IRTA2 gene structure and expression, we was not detected in any other myeloma or lymphoma
IRTAs, Immune Receptors Expressed in B Cells
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Figure 4. IRTA2 Expression Pattern
(A) Northern blot analysis of IRTA2 mRNA expression in multiple human tissues (left panel) and in lymphoid and non-lymphoid cell lines (right
panel) (2 mg mRNA per lane). Arrows, IRTA2 and GAPDH transcripts; a, b, c, and d, alternatively spliced IRTA2 mRNA isoforms. RD, NC42,
and CB33, EBV-transformed B lymphoblastoid cell lines; EREB, conditional EBV-transformed B lymphoblastoid cell line; FR4, myeloma cell
line; MOLT4 and HUT78, T cell lines; HL60 and U937, myelomonocytic cell lines; and K562, erythroid cell line.
(B) In situ hybridization analysis of IRTA2 mRNA expression in human tonsil. 1. Sense IRTA2 cDNA probe 2. Antisense IRTA2 cDNA probe 3.
H&E staining 4. Antisense IRTA2 cDNA probe signal superimposed over H&E stained section. GC, germinal center; and MargZ, marginal zone.
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Figure 5. Map of the Germline 1q21 Region at the FR4 Breakpoint and Genomic Organization of IRTA1 and IRTA2
Black and light boxes indicate coding and noncoding exons, respectively. Arrows indicate position of BCL9, MUC1, IRTA family and FCGRIIB
loci. S, SacI; H, HindIII; S, SwaI; Pc, PacI; P, PmeI; and Mb, Megabases.
cell line, regardless of the status of its chromosomal cases. These results indicate that, with the exception
band 1q21 (data not shown). Thus, the IRTA1/Ca fusion of FR4, the breakpoints of 1q21 aberrations in BL or
represents a rare event in 1q21 aberrations. MM are not within or in close proximity to the genomic
region defined by IRTA1 and IRTA2. However, the consis-
tent outcome of either dup(1)(q21q32) or dup(1)(q21q32)Frequent Deregulation of IRTA2 Expression
followed by unbalanced translocations (AS283A, BL136,in Cell Lines Carrying 1q21 Abnormalities
XG2, XG7), is partial trisomy or tetrasomy of the regionIn order to establish the physical relationship between
of 1q21 containing the IRTA genes.other 1q21 breakpoints and the IRTA1/2 locus, we per-
We then investigated whether these aberrations hadformed FISH analysis with the PAC 49A16 on our panel of
an effect on IRTA2 mRNA expression. A cDNA probeBL and MM cell lines. Among ten BL cell lines analyzed,
corresponding to the IRTA2 59 untranslated region wasseven with dup(1)(q21q32) and three with 1q21 translo-
used to screen Northern blots with panels of B-NHL andcations (AS283A, BL104, BL136), we detected three cop-
MM cell lines lacking or displaying 1q21 chromosomalies of the IRTA1/IRTA2 locus in seven of the former and
abnormalities. Most (ten out of twelve) BL lines analyzedtwo of the latter, consistent with dup(1)(q21q32) in the
with normal 1q21 chromosomes essentially lackedfirst group and dup(1)(q21q32) followed by a transloca-
IRTA2 expression, consistent with the fact that BL derivetion breakpoint at 1q21 in the second (data not shown).
from GC centroblasts that normally lack IRTA2 expres-FISH analysis of AS283A and BL136 with probes span-
sion (representative examples in Figure 7A, left panel).ning the IRTA locus and with neighboring genomic
In contrast, most BL lines carrying 1q21 abnormalitiesclones placed the breakpoint of the derivative chromo-
(ten out of twelve) clearly displayed IRTA2 mRNA upreg-somes outside the IRTA locus in both cell lines, at a
ulation (representative examples in Figure 7A, right panel),distance of .800 kb toward the centromere in AS283A
ranging from 2- to 50-fold over baseline levels detectedand .800 kb toward the telomere in BL136 (N. P, unpub-
in BL with normal 1q21. Among myeloma cell lines, IRTA2lished data). Consistent with this finding, analysis of 30
was overexpressed in one out of three lines displayingcases of MM primary tumors by interphase FISH with
1q21 abnormalities (XG2), while it was expressed in nonethe 300 kb YAC 23GC4 (Figure 5), determined that 15
out of seven with normal 1q21 (Figure 7B).cases had more than two interphase FISH signals (data
These results show a strong correlation between thenot shown). However, double color FISH with two PAC
presence of 1q21 chromosomal aberrations and deregu-clones flanking the YAC centromeric and telomeric bor-
ders detected no split of these two probes in any of the lation of IRTA2 mRNA expression in BL and suggest
IRTAs, Immune Receptors Expressed in B Cells
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Figure 6. t(1;14)(q21;q32) in FR4 Generates an IRTA1/Ca Fusion Transcript
(A) Schematic representation of the der(14) genomic clone lFR4B-5 and of the germline IgCa1 locus. Arrow, FR4 breakpoint; filled and open
boxes, IRTA1 and Ca1 coding and noncoding exons, respectively. (B) Northern blot analysis with an IRTA1 exon 1 probe (bar in [A]) on FR4
and additional cell lines (2 mg of polyA1 RNA per lane). Arrowheads, normal IRTA1 message in ER/EB mRNA. JJN3 and U266, myeloma cell
lines. (C) Schematic representation of the IRTA1/Ca fusion cDNA in FR4, amplified using the primers shown in (A). (D) SDS/PAGE analysis of
immunoprecipitates obtained from vector control and IRTA1/Ca transient expression construct transfected 293-T cells (lanes 1 and 2), or the
following cell lines: mIgA positive lymphoblastoid cell line-Dakiki (lane 3), FR4 (lane 4), mIgM positive NHL cell line-Ramos (lane 5). H, HindIII;
B, BamHI; X, XhoI; Sa, IgA switch region; EC, extracellular region; TM, transmembrane; and CYT, cytoplasmic.
that trisomies of the IRTA2 locus may deregulate its In their extracellular domain, the IRTA proteins are
closely related to the Fc receptor subfamily based onexpression in this lymphoma subtype.
the high degree of amino acid homology they share, in
particular with the high-affinity FCGRI receptor (37%–Discussion
45% amino acid identity). A common evolutionary origin
with Fc receptors is also suggested by the position ofIRTA1 and IRTA2 Are Founding Members
of a Subfamily within the Ig Superfamily the IRTA family locus in the interval between the FCGRI
locus on 1q21 and the FCERI and FCGRII-III loci onSeveral features shared between the two IRTA genes
and their encoded proteins suggest that they form a 1q21-q23. Finally, the IRTA and FCR genes share a simi-
lar exon/intron organization of the gene portion thatsubfamily within the immunoreceptor superfamily. First,
they share a higher degree of homology with each other encodes their signal peptide: two 59 leader exons and
location of the signal peptidase site within the secondin their extracellular domains than with other superfamily
members both in their mRNA (68% identity) and protein 21 bp exon.
Based on their cytoplasmic ITIM-like motifs, the IRTA(47% identity) sequence. Second, they share homology
in their cytoplasmic domains, marked by the presence proteins can be considered members of the inhibitory
receptor superfamily (IRS), a group of receptors thatof ITAM-like and ITIM signaling motifs in the context of
homologous amino acid sequences. Third, IRTA1 and block activation of many cell types in the immune system
(reviewed in Ravetch and Lanier, 2000). Such membersIRTA2 belong to a larger subfamily of five genes dis-
playing higher intrafamily homology and tight clustering include FCGRIIB and CD22 in the human (DeLisser et
al., 1994) and PIR-B in the mouse (Kubagawa et al.,within an z300 kb region at 1q21 (I. M. et al., unpublished
data). Their genomic organization suggests that a com- 1997). Analogous to IRS members, the ITIM of IRTA1
and IRTA2 are encoded by individual exons. A featuremon ancestral gene may have given rise to this subfam-
ily, by a process of duplication and sequence diver- shared by many IRS members is the presence of activat-
ing receptor isoforms whose cytoplasmic domains aregence, similar to the mechanism proposed for the Fc
receptor family (Qiu et al., 1990). devoid of ITIM (Ravetch and Lanier, 2000). It is possible
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Figure 7. IRTA2 Expression Is Deregulated in Cell Lines Carrying 1q21 Abnormalities
(A and B) Northern blot analysis of IRTA2 mRNA expression in representative Burkitt lymphoma (A) and multiple myeloma (B) cell lines (2 mg
mRNA per lane). The positions of the IRTA2 and GAPDH transcripts are shown by dashes and arrows, respectively. The relative levels of
IRTA2 mRNA expression in all 1q21 normal and abnormal cell lines analyzed are plotted in the right panel (A) after densitometric analysis and
normalization versus GAPDH levels. The right panel in (B) is a summary of all the Northern blot analysis data.
that the secreted isoform of IRTA2, which lacks ITIM- IgG, IgA, IgM, and IgE (data not shown). These initial
data lend support to a functional relationship betweenlike motifs, fulfills an analogous activating role by coun-
teracting the effect of the transmembrane isoform. the IRTA and the Fc receptor families but do not exclude
functions dependent on other ligands for the IRTA pro-Significant homology in the sequence and overall or-
ganization of their extracellular portion is shared among teins.
the IRTA1 and IRTA2 proteins and the cell adhesion
molecule (CAM) subfamily members PECAM1, CD22,
and BGP1. In addition, the ability of IRTA2 to generate Differential Pattern of Expression of IRTA
Genes in Mature B Cellsthree protein isoforms with distinct subcellular localiza-
tion (a transmembrane, a GPI-linked, or a secreted pro- The IRTA genes display a specific pattern of expression
in various normal B cell compartments. IRTA1 is topo-tein) by differential splicing is shared by NCAM, another
member of the CAM subfamily (Dickson et al., 1987; graphically restricted to B cells within the perifollicular
region, which was originally named marginal zone in theGower et al., 1988). Thus, the IRTA family is also related
to the CAM family, as has been previously suggested spleen, but is also detectable in most lymphoid organs
(de Wolf-Peeters et al., 1997). On the other hand, IRTA2for a member of the Fc receptor family (murine FCGRII)
because of its homology to PECAM1 (CAM, IRS family) has a broader pattern of expression that includes GC
centrocytes and a broad spectrum of perifollicular cells,(Newman et al., 1990).
In conclusion, the IRTA family may represent an inter- which may include immunoblasts and memory cells.
Initial data suggest that the pattern of expression ofsection among the Fc, IRS, and CAM families, combining
features from all three. Accordingly, IRTA proteins may IRTA3 is analogous to IRTA2, while IRTA4 and IRTA5
are selectively expressed in mantle zone B cells (I. M.have a role in the regulation of signal transduction during
an immune response, intercellular communication and et al., unpublished data), the pre-GC compartment of
mature B cells (Kuppers et al., 1999). This topographiccell migration (DeLisser et al., 1994; Ravetch and Lanier,
2000). Initial experiments indicate that IRTA1 can weakly restriction of IRTA gene expression in lymphoid organs
suggests that the IRTA molecules may play a role in thebind heat aggregated IgA, while IRTA2c can specifically
bind heat aggregated human serum IgG (with higher migration or activity of various B cell subpopulations in
specific functional B cell compartments.affinity for IgG1 and IgG2), but not monomeric human
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IRTA1 Locus and 1q21 Abnormalities in MM light zone of the GC, suggest that its ectopic expression
in centroblasts may cause a disruption in the GC devel-In the FR4 cell line, the consequence of the t(1;14) trans-
location is the formation of an IRTA1/Ca1 fusion gene. opment and architecture. On the other hand, our initial
observations that IRTA2 can bind IgG immune com-Despite the fact that this gene is driven by the IRTA1
promoter region, which is normally silent in plasma cells, plexes comparably to bona fide Fc receptors suggest
that its inappropriate expression may perturb the dy-its expression is high in FR4, presumably due to the
influence of the Ca1 39 LCR, which is retained down- namics of cell surface regulation of B cell immunological
responses, possibly leading to clonal expansion. Dereg-stream of the Ca1 locus. The fusion gene encodes a
IRTA1/Ca1 fusion protein that contains only the signal ulated expression of FCGR2B as a result of the t(1;14)
(q21;q32) in follicular lymphoma has been proposed topeptide and first two amino acids of IRTA1 linked to
the surface IgA receptor. The latter has been almost contribute to lymphomagenesis in this tumor type (Cal-
lanan et al., 2000), by a mechanism involving escape bycompletely deprived of its extracellular domain but re-
tains all its transmembrane and intracellular domains. tumor cells of antitumor immune surveillance through
their Fc binding and inactivation of tumor-specific IgG.This structure indicates that the IRTA1/Ca1 fusion pro-
tein, though probably unable to bind any ligand, may Similar evasion mechanisms have been observed in
cells infected by Fc-encoding herpesvisures (Dubin etretain the potential for dimerization and signaling. The
fusion protein also carries the intact, 14 amino acid mIgA al., 1991). The role of IRTA2 deregulation needs to be
tested in “gain of function” transgenic mice constitu-cytoplasmic domain, which is highly conserved in evolu-
tion (Reth, 1992) and may play an essential role in the tively expressing IRTA2 in the GC.
proliferation, survival, and differentiation of mature B
Experimental Procedurescells, analogous to the role of mIgG and mIgE (Kaisho
et al., 1997). Thus, the emergence of the IRTA1/Ca1 pro-
Cell Linestein in FR4 may have provided the cells with a prolifera- The MM cell lines used in this study (FR4, U266, JJN3, EJM, SKMM1,
tive and survival advantage during tumor development RPMI-8226, XG1, XG2, XG4, XG6, and XG7) have been previously
through ligand (antigen)-independent activation of the described (Jernberg et al., 1987; Eton et al., 1989; Jackson et al.,
1989; Hamilton et al., 1990; Tagawa et al., 1990; Zhang et al., 1994).BCR pathway. This fusion event however, appears to
The U266, JJN3, and EJM cell lines were gifts from Dr .K. Nilssonbe rare in B cell malignancy, since so far we were able
(University of Uppsala, Sweden), and the SKMM-1 cell line was ato detect it only in FR4 cells.
gift of A.N. Houghton (MSKCC, NY). The five XG cell lines were
obtained from Dr. Bernard Klein and cultured in the presence of 1
IRTA2 Locus and 1q21 Abnormalities in MM and BL ng/ml human recombinant IL-6 as described previously (Zhang et
al., 1994). The BL cell lines with 1q21 abnormalities were previouslyAbnormal expression of IRTA2 is a frequent conse-
described (Magrath et al., 1980; Polito et al., 1995) and grown inquence of 1q21 abnormalities. Although this gene is not
RPMI, 10% FCS.expressed normally either in centroblasts, the presumed
normal counterparts of BL (Kuppers et al., 1999), or in
Genomic and cDNA Library Screening and DNA
BL with normal 1q21, its levels are upregulated on aver- Sequence Analysis
age by 10-fold in BL cell lines with 1q21 abnormalities. Two genomic libraries were constructed from FR4 genomic DNA
This deregulation appears to be specific for IRTA2 since either by BamHI complete digestion or by Sau3AI partial digestion
and ligation of gel-purified fractions into the lDASH-II phage vectorall the other 4 IRTA genes present within 300 kb on 1q21
(Stratagene). The BamHI library was screened with a 4.2 kb XhoI-are either not expressed in BL (IRTA1) or their pattern
BamHI Ca locus probe and the Sau3AI library with a 59Sa probeof expression does not correlate with the presence of
previously described (Bergsagel et al., 1996). A human placental
1q21 abnormalities (IRTA3, 4, 5, not shown). The mecha- DNA library (Stratagene) was screened with probe 1.0EH (Figure 1)
nism by which this deregulation occurs is difficult to to obtain the germline 1q21 locus. Library screening and plaque
ascertain in the absence of structural lesions within or isolation were performed according to established procedures
(Sambrook et al., 1989). IRTA1 and IRTA2 cDNA clones were isolatedadjacent to the IRTA2 gene. Since the heterogeneous
from an oligo-dT/random-primed cDNA library constructed fromaberrations that affect 1q21 all cause an excess copy
normal human spleen RNA (Clontech). The IRTA1 cDNA probe usednumber of the IRTA locus, it is possible that this may
for library screening was obtained from RT-PCR of human spleen
lead to regulatory disturbances, as is the case for low- cDNA using primers flanking exons 1 and 3. DNA sequencing was
level amplification of BCL2 in FL lacking (14;18) translo- preformed on an ABI 373 automated sequencer (Applied Bio-
cations (Monni et al., 1997), REL in DLCL (Rao et al., systems).
1998), and deregulation of Cyclin D1 in some MM cases
PAC and YAC Isolation and Exon Trappingwith trisomy 11 (Pruneri et al., 2000). On the other hand,
Human PAC clones were obtained by screening a human PAC library1q21 abnormalities, including translocations and dupli-
(Research Genetics) with the 1.0 EH probe (Figure 1). The Zenecacations, change the genomic context of the IRTA locus
(formerly ICI) human YAC library (Anand et al., 1990) (United King-
and may lead to deregulation of IRTA2 by distant cis- dom Human Genome Mapping Resource Center) was screened us-
acting enhancer chromatin organizing elements acting ing a PCR-based pooling strategy. Exon trapping was performed
on its promoter as is the case for MYC in endemic BL using the exon trapping system (Gibco BRL), according to the manu-
facturer’s instructions.(Grignani et al., 1990) and MM (Shou et al., 2000) and
for CCND1 in MCL (Swerdlow et al., 1995) and MM (Prun-
Isolation of PAC/YAC End Clones, Pulsed-Field Geleri et al., 2000).
Electrophoresis, and Fluorescence In Situ Hybridization AnalysisThe biological consequences of deregulated IRTA2
PAC DNA extraction was performed by standard alkaline lysis and
expression are difficult to predict at this stage. The ob- PAC or YAC end probes were isolated by a vectorette-PCR method
servation that IRTA2 has homology with CAM adhesion (Drakopoli et al., 1997). Biotin labeling of PAC DNA, chromosome
preparation, fluorescence in situ hybridization (FISH), and pulsed-receptors, together with its specific distribution in the
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field gel electrophoresis (PFGE) analysis using the CHEF Mapper lin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad.
Sci. USA 93, 13931–13936.system (BioRad) were performed as previously described (Rao et
al., 1993; Drakopoli et al., 1997). Callanan, M.B., Le Baccon, P., Mossuz, P., Duley, S., Bastard, C.,
Hamoudi, R., Dyer, M.J., Klobeck, G., Rimokh, R., Sotto, J.J., et al.
Southern and Northern Blot Analyses, RACE, and RT-PCR (2000). The IgG Fc receptor, FcgammaRIIB, is a target for deregula-
Southern and Northern blot analyses were performed as described tion by chromosomal translocation in malignant lymphoma. Proc.
previously (Neri et al., 1991). For Northern blot analyses, total RNA Natl. Acad. Sci. USA 97, 309–314.
was prepared by the guanidium thiocyanate method and poly(A)
Chesi, M., Kuehl, W.M., and Bergsagel, P.L. (2000). Recurrent immu-
RNA was selected using poly(T)-coated beads (Oligotex Kit by Qui-
noglobulin gene translocations identify distinct molecular subtypes
gen). Multiple tissue Northern filters were obtained from Clontech.
of myeloma. Ann. Oncol. 11, 131–135.
RACE was performed using the Marathon cDNA Amplification kit
Cigudosa, J.C., Parsa, N.Z., Louie, D.C., Filippa, D.A., Jhanwar, S.C.,(Clontech) and Marathon-Ready spleen cDNA and first strand cDNA
Johansson, B., Mitelman, F., and Chaganti, R.S. (1999). Cytogeneticsynthesis with the Superscript RT-PCR system (Gibco BRL)
analysis of 363 consecutively ascertained diffuse large B- cell lym-
phomas. Genes Chromosomes Cancer 25, 123–133.In Situ Hybridization
Dalla-Favera, R., and Gaidano, G. (2001). Molecular biology of lym-Digoxigenin-containing antisense and sense cRNA probes were
phomas. In Cancer: Principles and Practice of Oncology, Sixth Ed,transcribed with T3 and T7 RNA polymerase, respectively, from
V.T. DeVita, S. Hellman, and S.A. Rosenberg, eds. (Philadelphia, PA:linearized pBluescript KS1 plasmids containing coding region of
Lippincott Williams and Wilkins), pp. 2215–2235.cDNAs (nt 62 to 1681 of IRTA1 and 18 to 2996 of IRTA2.) Hyperplastic
human tonsillar tissue surgically resected from children in Babies’ de Wolf-Peeters, C., Pittaluga, S., Dierlamm, J., Wlodarska, I., and
Hospital, Columbia Presbyterian Medical Center, was snap frozen Van Den Berghe, H. (1997). Marginal zone B-cell lymphomas includ-
in powdered dry ice. Cryostat sections were stored for several days ing mucosa-associated lymphoid tissue type lymphoma (MALT),
at 2808C prior to processing. Nonradioactive in situ hybridization monocytoid B-cell lymphoma and splenic marginal zone cell lym-
was performed essentially as described (Frank et al., 1999), except phoma and their relation to the reactive marginal zone. Leuk. Lym-
that fixation time in 4% paraformaldehyde was increased to 20 phoma 26, 467–478.
min, and proteinase K treatment was omitted. The stringency of
DeLisser, H.M., Newman, P.J., and Albelda, S.M. (1994). Molecular
hybridization was 688C, in 53 SSC, 50% formamide. Alkaline phos-
and functional aspects of PECAM-1/CD31. Immunol. Today 15,
phatase-conjugated antidigoxigenin antibody staining was devel-
490–495.
oped with BCIP/NBT substrate.
Dickson, G., Gower, H.J., Barton, C.H., Prentice, H.M., Elsom, V.L.,
Moore, S.E., Cox, R.D., Quinn, C., Putt, W., and Walsh, F.S. (1987).Transfection, Immunoprecipitation, and Western Blot
Human muscle neural cell adhesion molecule (N-CAM): identification293 cells (ATCC), grown in DMEM, 10% FCS were transiently trans-
of a muscle-specific sequence in the extracellular domain. Cell 50,fected, according to the standard calcium phosphate method, with
1119–1130.pMT2T and pMT2T-IRTA1/Ca expression constructs. The latter was
Dierlamm, J., Pittaluga, S., Wlodarska, I., Stul, M., Thomas, J., Boo-generated using the IRTA1/Ca RT-PCR product from FR4. Cells (2 3
gaerts, M., Michaux, L., Driessen, A., Mecucci, C., Cassiman, J.J.,106 of transfectants and 2 3 107 of cell lines) were solubilized in
et al. (1996). Marginal zone B-cell lymphomas of different sites shareTriton X-100 lysis buffer (150 mM NaCl, 10 mM Tris-HCl [pH 7.4],
similar cytogenetic and morphologic features. Blood 87, 299–307.1% Tx-100, and 0.1% BSA) in the presence of a protease inhibitors
coctail (Roche Biochemicals). Lysates were incubated at 48C for 2 Drakopoli, C.N., Haines, J.L., Korf, B.R., Morton, C.C., Seidman,
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1990) (Tanox Biosystems, Inc) against the extracellular portion of Hum. Genet. (New York: Wiley & Sons).
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protein G-Sepharose (Pharmacia) prior to electrophoresis on 10%– simplex virus type 1 Fc receptor protects infected cells from anti-
20% Tris-HCl gradient gels (Biorad) and immunobloting, using 15 body-dependent cellular cytotoxicity. J. Virol. 65, 7046–7050.
mg/ml of the #117-332-1 antibody. Results were visualized by ECL
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